Literature DB >> 8843581

Purification and characterization of a fibrinogen-clotting enzyme from the venom of jararacuçu (Bothrops jararacussu).

G L Zaganelli1, M G Zaganelli, A Magalhães, C R Diniz, M E de Lima.   

Abstract

A clotting enzyme of the venom of Bothrops jararacussu, denoted FC-Bj, was purified by gel chromatography on Sephadex G-100 followed by HPLC on DEAE-5PW-PAK and gel filtration on Sephacryl S-200HR. The enzyme was identified as an acidic glycoprotein which probably consists of a single polypeptide chain with isoelectric point values in the range 3.3-4.4 and containing approx. 19% carbohydrates. On polyacrylamide gel electrophoresis (PAGE) at pH 8.3, the enzyme presented a diffuse protein band. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the enzyme showed two protein bands corresponding to mol. wts of 50,600 and 60,000. After treatment of the enzyme with neuraminidase, a strongly stained band and a band weaker in staining intensity were observed on SDS-PAGE, thereby reducing the mol. wts to 44,500 and 56,300, respectively. The clotting factor possessed N-alpha-benzoyl-DL-arginine p-nitroanilide hydrolysing activity and coagulated fibrinogen to fibrin. These activities were 0.548 units/mg and 50.55 NIH thrombin units/mg, respectively. The proteinase was of the serine type, as indicated by sensitivity to phenylmethanesulfonyl fluoride and benzamidine. However, the amidolytic activity of this enzyme was resistant to inhibitors such as heparin, aprotinin, agmatine, EDTA, I-2581 and TLCK. The importance of disulfide bridges for the structural integrity of the purified enzyme was indicated by the loss of amidolytic activity in the presence of beta-mercaptoethanol and dithiothreitol. SDS-PAGE of fibrinogen degraded with this enzyme revealed the disappearance of the A alpha and B beta chains and the appearance of lower mol. wt fragments. The enzyme was able to hydrolyse synthetic chromogenic substrates with arginine as the C-terminal residue, and the kinetic parameters were determined. It hydrolysed the plasma kallikrein substrate H-D-Pro-Phe-Arg-pNA (S-2302) and produced kinin-releasing activity causing ileum contraction. In addition, hypotension and bradycardia were observed in urethane-anesthetized rats upon i.v. injection of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843581     DOI: 10.1016/0041-0101(96)00006-2

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  5 in total

1.  Hemostatic and toxinological diversities in venom of Micrurus tener tener, Micrurus fulvius fulvius and Micrurus isozonus coral snakes.

Authors:  Ana M Salazar; Jeilyn Vivas; Elda E Sánchez; Alexis Rodríguez-Acosta; Carlos Ibarra; Amparo Gil; Zoila Carvajal; María E Girón; Amalid Estrella; Luis F Navarrete; Belsy Guerrero
Journal:  Toxicon       Date:  2011-05-08       Impact factor: 3.033

2.  A transcriptomic analysis of gene expression in the venom gland of the snake Bothrops alternatus (urutu).

Authors:  Kiara C Cardoso; Márcio J Da Silva; Gustavo G L Costa; Tatiana T Torres; Luiz Eduardo V Del Bem; Ramon O Vidal; Marcelo Menossi; Stephen Hyslop
Journal:  BMC Genomics       Date:  2010-10-26       Impact factor: 3.969

3.  Snake venoms are integrated systems, but abundant venom proteins evolve more rapidly.

Authors:  Steven D Aird; Shikha Aggarwal; Alejandro Villar-Briones; Mandy Man-Ying Tin; Kouki Terada; Alexander S Mikheyev
Journal:  BMC Genomics       Date:  2015-08-28       Impact factor: 3.969

4.  Bmoo FIBMP-I: A New Fibrinogenolytic Metalloproteinase from Bothrops moojeni Snake Venom.

Authors:  F S Torres; B Rates; M T R Gomes; C E Salas; A M C Pimenta; F Oliveira; M M Santoro; M E de Lima
Journal:  ISRN Toxicol       Date:  2012-11-04

Review 5.  Vipers of the Middle East: A Rich Source of Bioactive Molecules.

Authors:  Mohamad Rima; Seyedeh Maryam Alavi Naini; Marc Karam; Riyad Sadek; Jean-Marc Sabatier; Ziad Fajloun
Journal:  Molecules       Date:  2018-10-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.